Gain Therapeutics Inc Cash Flow Conversion Efficiency
Gain Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Gain Therapeutics Inc (GANX) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.62 Million) by net assets ($18.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Gain Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Gain Therapeutics Inc from 2018 to 2025. This chart illustrates how Gain Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Gain Therapeutics Inc stock price today for real-time trading data and today's change.
Gain Therapeutics Inc Cash Flow Conversion Ratio Explained
Gain Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Gain Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gain Therapeutics Inc ranked by their cash flow conversion efficiency. Also see GANX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FELIX Gold Ltd
AU:FXG
|
-0.022x |
|
Sekar Bumi Tbk
JK:SKBM
|
0.219x |
|
First Breach Inc. Common Stock
NASDAQ:FBDT
|
-2.734x |
|
TNR Gold Corp.
V:TNR
|
-0.126x |
|
EnerSyn Global Inc.
NASDAQ:ESYN
|
0.171x |
|
Yarrow Bioscience Inc
NASDAQ:YARW
|
-0.166x |
|
SM Culture & Contents Co. Ltd
KQ:048550
|
0.055x |
|
LABIANA HEALTH S.A.EO-10
F:8RK
|
N/A |
Annual Cash Flow Conversion Efficiency for Gain Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Gain Therapeutics Inc from 2018 to 2025. Review GANX financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.56 Million | $-18.47 Million | -0.995x | +61.32% |
| 2024-12-31 | $7.34 Million | $-18.87 Million | -2.572x | -71.45% |
| 2023-12-31 | $12.58 Million | $-18.87 Million | -1.500x | -92.74% |
| 2022-12-31 | $18.88 Million | $-14.69 Million | -0.778x | -119.12% |
| 2021-12-31 | $34.82 Million | $-12.37 Million | -0.355x | +32.02% |
| 2020-12-31 | $6.20 Million | $-3.24 Million | -0.522x | -112.58% |
| 2019-12-31 | $-449.86K | $-1.87 Million | 4.154x | +430.50% |
| 2018-12-31 | $-950.91K | $-744.51K | 0.783x | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more